- Home
- PPTA vs LEGN Comparison
PPTA vs LEGN Comparison
Compare PPTA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPTA | LEGN |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | 3200 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.6B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PPTA | LEGN |
|---|---|---|
| Price | $23.40 | $18.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $37.38 | ★ $61.33 |
| AVG Volume (30 Days) | 841.6K | ★ 1.6M |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.68 |
| Revenue Next Year | N/A | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.44 | $16.24 |
| 52 Week High | $37.37 | $37.50 |
Technical Indicators
Market Signals| Indicator | PPTA | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.86 | 42.38 |
| Support Level | $23.87 | $17.81 |
| Resistance Level | $26.34 | $19.36 |
| Average True Range (ATR) | 0.87 | 0.77 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 54.67 | 34.49 |
Price Performance
Historical ComparisonAbout PPTA Perpetua Resources Corp.
Perpetua Resources Corp is engaged in acquiring mining properties with the intention of exploring, evaluating, developing and placing them into production, if warranted. Its principal mineral project is the Stibnite Gold Project in Idaho, USA, which contains several gold, silver and antimony mineral deposits. The company's current focus is to redevelop three of the Deposits known as the Hangar Flats Deposit, West End Deposit and Yellow Pine Deposit, all of which are located within the Stibnite Gold Project, as well as reprocess certain historical tailings located on the Project. It operates in one segment: mineral exploration and development in the United States.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.